This core's mission is to facilitate translational and laboratory-based research performed by all program investigators. The core supports 4 functions: 1) processing and cryopreservation of primary AML and MDS samples; 2) annotation of primary samples with pathologic, cytogenetic and flow cytometry data; 3) annotation of primary AML samples with genomic and functional data; and 4) maintain a bank of AML cell lines, primagrafts and in vitro models suitable for functional assays. As of November 2018, 12,790 bone marrow samples have been banked from 3,590 unique patients with hematologic malignancies. All of these samples were obtained from patients enrolled on IRB-approved sample collection protocol DF/HCC 01-206: Blood and Bone Marrow Sample Collection for Research Studies in Patients with Hematologic Malignancies, Bone Marrow Disorders, and Normal Donors. The bank includes samples from 1473 patients with AML and 634 patients with MDS. The samples have been extensively used to support clinical and laboratory research over the last five years in support of drug development, analysis of oncogene function and prognosis, development of BH3 profiling, creation of a large bank of genomically defined PDX models of AML, and other laboratory studies.

Public Health Relevance

This Shared Resource Core will collect blood and/or marrow samples from patients with AML or MDS and preserve viable cells, RNA, and DNA from adult patients receiving treatment at DFCI or BWH, along with annotated clinical and genomic data from these patients. The Core makes these samples available for clinical or research studies carried out in each of the projects in this grant.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Dana-Farber Cancer Institute
United States
Zip Code
Weinberg, Olga K; Gibson, Christopher J; Blonquist, Traci M et al. (2018) Association of mutations with morphological dysplasia in de novo acute myeloid leukemia without 2016 WHO Classification-defined cytogenetic abnormalities. Haematologica 103:626-633
Hoshii, Takayuki; Cifani, Paolo; Feng, Zhaohui et al. (2018) A Non-catalytic Function of SETD1A Regulates Cyclin K and the DNA Damage Response. Cell 172:1007-1021.e17
Gooptu, Mahasweta; Kim, Haesook T; Chen, Yi-Bin et al. (2018) Effect of Antihuman T Lymphocyte Globulin on Immune Recovery after Myeloablative Allogeneic Stem Cell Transplantation with Matched Unrelated Donors: Analysis of Immune Reconstitution in a Double-Blind Randomized Controlled Trial. Biol Blood Marrow Transplant 24:2216-2223
Gutierrez-Martinez, Paula; Hogdal, Leah; Nagai, Manavi et al. (2018) Diminished apoptotic priming and ATM signalling confer a survival advantage onto aged haematopoietic stem cells in response to DNA damage. Nat Cell Biol 20:413-421
Nabet, Behnam; Roberts, Justin M; Buckley, Dennis L et al. (2018) The dTAG system for immediate and target-specific protein degradation. Nat Chem Biol 14:431-441
Kleppe, Maria; Koche, Richard; Zou, Lihua et al. (2018) Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms. Cancer Cell 33:29-43.e7
List, Alan; Ebert, Benjamin L; Fenaux, Pierre (2018) A decade of progress in myelodysplastic syndrome with chromosome 5q deletion. Leukemia 32:1493-1499
Ebert, Benjamin L; Krönke, Jan (2018) Inhibition of Casein Kinase 1 Alpha in Acute Myeloid Leukemia. N Engl J Med 379:1873-1874
Sellar, Rob S; Jaiswal, Siddhartha; Ebert, Benjamin L (2018) Predicting progression to AML. Nat Med 24:904-906
Hshieh, Tammy T; Jung, Wooram F; Grande, Laura J et al. (2018) Prevalence of Cognitive Impairment and Association With Survival Among Older Patients With Hematologic Cancers. JAMA Oncol 4:686-693

Showing the most recent 10 out of 376 publications